"We were grateful for this opportunity to meet with our world-class Scientific Advisory Board," explained Paul Sheils, Chief Executive Officer of InterCure. "These are some of the world’s most distinguished experts on hypertension and the people involved in setting the guidelines and standards for the medical community to manage hypertension. It means a great deal that they support RESPeRATE as an effective treatment of hypertension."
The Scientific Advisory Board (SAB) is composed of several of the world’s most renowned opinion-leaders in the field of hypertension, including:
Henry R. Black, M.D., Head of the Preventive Medicine Department at Rush University, Chicago, IL, who served on the Executive Committee of the Sixth Joint National Committee on the Detection, Evaluation, and Treatment of Hypertension (JNC VI), served on the Executive Committee of the American Heart Association Council on High Blood Pressure Research, and was a member of the Executive Committee of the American Society of Hypertension;
Jay N. Cohn, M.D., Professor of Medicine, Cardiovascular Division, Department of Medicine at the University of Minnesota Medical School in Minneapolis, President of the Heart Failure Society of America, President of the International Society of Hypertension, past President of The American Society of Hypertension, former officer of the American Heart Association, and former chairman of the Cardiorenal Advisory Committee of the Food and Drug Administration;
Ehud Grossman, M.D., Head of the Department of Internal Medicine at the Chaim Sheba Medical Center, Tel-Hashomer, Israel, who serves on the council of the Israeli Society of Hypertension, recognized as a hypertension specialist of the European Society of Hypertension, and serves as a consultant in hypertension to the two largest HMOs in Israel, Kupat Holim and Maacabi in Israel;
Joseph L. Izzo, M.D., Professor of Medicine and Professor of Pharmacology & Toxicology at the University of Buffalo, NY, and Vice Chair of Research for the Department of Medicine, who sits on the American Heart Association’s Continuing Education Committee and has published extensively in areas such as the mechanisms of hypertension and stress responses of blood pressure;
Giuseppe Mancia, M.D., Professor of Medicine at the University of Milan-Bicocca, Italy and Chairman of the Department of Medicine at the S. Gerardo Hospital, Monza, Milan., Italy, who served as President and Secretary of the International Society of Hypertension, served as President of the Italian Society of Hypertension, is President of the European Society of Hypertension (ESH), and is a member of the Executive Scientific Council of the American Society of Hypertension; and
Thomas Pickering, M.D., PhD, FRCP, Director of the Integrative and Behavioral Cardiology Program of the Cardiovascular Institute at Mount Sinai School of Medicine, New York, author of the Sixth Report of the Joint National Committee for Prevention, Detection, Evaluation and Treatment of Hypertension (JNC VI), member of the American Heart Association’s Council for High Blood Pressure Research, who served as Secretary of the American Society of Hypertension, and on the National Heart, Lung and Blood Institute’s task forces on hypertension and behavioral medicine.
The members of the Scientific Advisory Board were also joined by other opinion leaders including Norman Kaplan, M.D. (The University of Texas Southwestern Medical Center at Dallas), Talma Rosenthal, M.D. (Tel Aviv University’s Sackler Faculty of Medicine), Gianfranco Parati, M.D. (Istituto Scientifico Ospedale S. Luca, Istituto Auxologico Italiano, Milan, Italy), and Reuven Viskoper, M.D. (Barzilai Medical Centre, Ashkelon, Israel).
The advisory board meeting was held to review the clinical progress and to advise InterCure leadership as to how to best help patients with its innovative therapeutic device technology. "We were pleased to update the Board with the progress and results of six clinical studies in the U.S. and abroad. They were very excited to review the efforts underway which study how breathing exercises may modify the cardiovascular system," said Dr. Benjamin Gavish, the Chief Scientist of InterCure and the inventor of the RESPeRATE technology, "This is further strengthening evidence of RESPeRATE’s effectiveness as another non-drug option to lower high blood pressure."
RESPeRATE (http://www.resperate.com) received market clearance from the US Food and Drug Administration (FDA) for the adjunctive treatment of hypertension. RESPeRATE is the first non-invasive, non-drug therapeutic device indicated for the adjunctive treatment of hypertension. In controlled clinical trials, RESPeRATE has been demonstrated to reduce blood pressure, with no side effects.
"RESPeRATE offers an exciting new option, in fact, a whole new therapeutic class for the treatment hypertension", noted Dr. Cohn. "The potential for both patients and physicians to benefit from this non-pharmacological treatment to lower blood pressure with no side effects makes RESPeRATE an extremely attractive alternative."
Cumulatively, these seven hypertension experts on the InterCure board have published hundreds of peer-reviewed studies and textbooks on various aspects of cardiovascular diseases. Dr. Black sits on the editorial board of the Journal of Hypertension and the Journal of Human Hypertension. Dr. Cohn is editor-in-chief of the Journal of Cardiac Failure and co-authored the classic text, Cardiovascular Medicine. Dr. Mancia has been a member of the editorial boards of more than 30 international hypertension journals, has been chief or associate editor of various international hypertension journals and is presently deputy editor of the Journal of Hypertension. Cambridge and Oxford-educated Dr. Pickering, who founded the Hypertension Network and bloodpressure.com to help individuals with high blood pressure take charge of their condition, is on the editorial board of several journals in the fields of hypertension and behavioral medicine. Dr. Izzo is on the Editorial Board of the American Journal of Hypertension and the Journal of Clinical Hypertension. Dr. Grossman serves on the on the editorial board of the Journal of Human Hypertension.
About InterCure
InterCure (www.intercure.com) is an innovative medical device company developing a whole new class of non-drug treatments for some of the world’s most widespread and costly diseases. The company has patented a proprietary technology platform, which, based upon strong clinical evidence, is being used to develop innovative therapeutic medical devices to treat chronic diseases including hypertension, congestive heart failure (CHF), asthma, and chronic obstructive pulmonary diseases (COPD). InterCure utilizes a web-based reporting and support system to link its therapeutic devices with home diagnostic devices to increase compliance, provide physicians meaningful information and reduce healthcare costs.
For more information on InterCure or RESPeRATE, visit www.intercure.com or call 1-877-988-9388.